Alzheimer's company TauRx makes promising noises on Phase III trial

TauRx Pharmaceuticals, a company that claims to be the global leader in tau-based research in Alzheimer’s disease, has announced the unblinding of initial data from completion of the randomized portion of its pivotal Phase III trial, LUCIDITY.

The firm's lead investigative oral drug, hydromethylthionine mesylate (HMTM), has been tested in 598 people with Alzheimer’s. Following the 12-month blinded phase of the study, participants have moved forward to an additional one-year open label phase.

Claude Wischik, executive chairman and co-founder of TauRx, said: “The output indicates that participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer’s based on published research. This was seen for both cognitive and functional endpoints across a broad range of severity from mild cognitive impairment (MCI) to moderate Alzheimer’s. Importantly, the safety profile is favourable and consistent with previous studies.